Drugs / EOC202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03600090 | Oct 2018 → Dec 2021 | cancer | Taizhou EOC Pharma Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05322720 Comparator | Apr 2022 → Mar 2023 | cancer | Taizhou EOC Pharma Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-12-16 | Taizhou EOC Pharma Co., Ltd. | Results EOC202海外试验显著改善晚期乳腺癌患者总生存期，亿腾景昂药业在中国启动该产品II期临床 eocpharma.com ↗
这是全球首次观察到作为抗原递呈细胞（APC）激动剂的LAG3融合蛋白在随机双盲、安慰剂对照试验中使转移性乳腺癌患者的总生存期（OS）获益。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-12-06 | Taizhou EOC Pharma Co., Ltd. | EOC202（eftilagimod alpha）与PD-1通路抑制剂联合应用及与化疗药物联合应用的两项专利在中国获得授权 eocpharma.com ↗ |
| 2020-12-16 | Taizhou EOC Pharma Co., Ltd. | EOC202海外试验显著改善晚期乳腺癌患者总生存期，亿腾景昂药业在中国启动该产品II期临床 eocpharma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EOC202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03600090 ↗ |
| Known as | Eftilagimod Alpha | “EOC202 (Eftilagimod Alpha)” NCT03600090 ↗ |
| Modality | Protein / enzyme biologic | “hLAG-3 Fusion Protein” NCT03600090 ↗ |
| Route | Subcutaneous | “EOC202 will be SC injection.” NCT03600090 ↗ |